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Abstract
Background Patient-Reported Outcomes Measurement
Information System (PROMIS) tools can identify health-
related quality of life (HRQOL) domains that could differ-
entially affect disease progression. Cirrhotics are highly
prone to hospitalizations and re-hospitalizations, but the
current clinical prognostic models may be insufficient, and
thus studying the contribution of individual HRQOL
domains could improve prognostication.
Aim Analyze the impact of individual HRQOL PROMIS
domains in predicting time to all non-elective hospitaliza-
tions and re-hospitalizations in cirrhosis.
Methods Outpatient cirrhotics were administered PROMIS
computerized tools. The first non-elective hospitalization and
subsequent re-hospitalizations after enrollment were recor-
ded. Individual PROMIS domains significantly contributing
toward these outcomes were generated using principal com-
ponent analysis. Factor analysis revealed three major PRO-
MIS domain groups: daily function (fatigue, physical func-
tion, social roles/activities and sleep issues), mood (anxiety,
anger, and depression), and pain (pain behavior/impact)
accounted for 77% of the variability. Cox proportional haz-
ards regression modeling was used for these groups to eval-
uate time to first hospitalization and re-hospitalization.
Results A total of 286 patients [57 years, MELD 13, 67%
men, 40% hepatic encephalopathy (HE)] were enrolled.
Patients were followed at 6-month (mth) intervals for a
median of 38 mths (IQR 22–47), during which 31% were
hospitalized [median IQRmths 12.5 (3–27)] and 12%were re-
hospitalized [10.5 mths (3–28)]. Time to first hospitalization
was predicted by HE, HR 1.5 (CI 1.01–2.5, p = 0.04) and
daily function PROMIS group HR 1.4 (CI 1.1–1.8, p = 0.01),
independently. In contrast, the pain PROMIS group were
predictive of the time to re-hospitalizationHR 1.6 (CI 1.1–2.3,
p = 0.03) as was HE, HR 2.1 (CI 1.1–4.3, p = 0.03).
Conclusions Daily function and pain HRQOL domain
groups using PROMIS tools independently predict hospi-
talizations and re-hospitalizations in cirrhotic patients.
Keywords Cirrhosis  Healthcare-related quality of life 
Patient-reported outcomes  Hepatic encephalopathy 
Patient-Reported Outcomes Measurement Information
System
Abbreviations
HE Hepatic encephalopathy
MELD Model for End-Stage Liver Disease Health-
Related Quality of Life (HRQOL)
PRO Patient-reported outcomes
PROMIS Patient-Reported Outcomes Measurement
Information System
CAT Computerized adaptive measurement system
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Introduction
Cirrhosis is the 12th leading cause of overall death in the
USA [1]. Its prevalence will likely continue to increase due
to the epidemic of nonalcoholic fatty liver disease [2].
Cirrhosis is also a major cause of healthcare expenditure
[3], most of which is due to hospitalizations and re-hos-
pitalizations [4]. Furthermore, cirrhosis-related re-hospi-
talizations continue to remain excessively high with rates
ranging between 36 and 53% [5, 6] and likely
attributable to hepatic encephalopathy (HE). Current
methods to predict hospitalizations (and re-hospitaliza-
tions) remain challenging as using objective measures such
as the Model for End-Stage Liver Disease (MELD), serum
sodium, number of medications on discharge, age, history
of other complications of cirrhosis, and gender (i.e., male
sex), may be inadequate [7–12]. In addition, with the
progression of cirrhosis, there is also a parallel impairment
in patient-reported outcomes (PROs) such as health-related
quality of life (HRQOL) [13–15]. An impaired HRQOL in
cirrhosis can predict mortality [13, 16] and could contribute
to the significant financial and social burden to patients and
their families [13, 17]. Recent data suggest that even with
prior HE, cirrhotic patients have good insight regarding
their HRQOL [18], and these PROs can add a subjective
component to the prediction of outcomes such as HE
development [19].
Currently, the majority of research on health domains
within HRQOL measures has been studied within a frame-
work of an overall ‘‘total score’’ [20–23]. This approach is
not helpful to define individual PRO domains that could
predict negative outcomes [24–26]. Therefore, focusing on
specific domains or domain groups that specifically result in
hospitalizations/re-hospitalizations could guide clinicians
toward improving those in preventing these outcomes.
The Patient-Reported Outcomes Measurement Infor-
mation System computerized adaptive testing (PROMIS
CAT) [27–29] is a valid and dynamic instrument to mea-
sure and monitor changes of HRQOL in cirrhosis [30, 31].
It has several individual domains that can potentially serve
as predictors for hospitalizations/re-hospitalizations in
addition to objective parameters in cirrhosis. Therefore, the
aim of this study was to prospectively analyze the additive
impact of individual HRQOL domains generated using
PROMIS tools compared to objective markers of disease
severity in predicting time to all hospitalizations and re-
hospitalizations in patients with cirrhosis.
Materials and Methods
Study Population
Patients with cirrhosis were enrolled prospectively from
the hepatology clinics at Virginia Commonwealth
University Medical Center and McGuire VA Medical
Center from November 2009 to December 2015. Patients
who were excluded were those who were not able to give
informed consent and did not understand English. Because
of the potential impact on different domains within
HRQOL, we purposefully excluded those who were on
disability before diagnoses of cirrhosis, with other signifi-
cant end-stage organ diseases (i.e., congestive heart failure,
chronic obstructive pulmonary disease requiring oxygen,
and renal disease requiring dialysis) [32], and current
cancer diagnoses [33]. Similarly, we also excluded patients
with non-HE psychiatric conditions requiring hospitaliza-
tions, on chronic antipsychotics, and on anti-seizure med-
ications [34]. All included patients had cirrhosis proven on
a clinical basis involving laboratory tests, imaging findings,
endoscopic findings, and liver biopsy if available.
Demographic data and medication use were collected on
all patients. The etiology of cirrhosis was categorized into
viral hepatitis C, viral hepatitis C and alcoholic, alcoholic,
nonalcoholic steatohepatitis, and other (auto-immune hep-
atitis, etc.). The severity of liver disease at enrollment was
assessed in all patients by the MELD score. Serum
ammonia (lmol/L), serum sodium (mmol/L), and serum
albumin (g/dL) were recorded at time of enrollment.
Education was recorded in years. Prior history of episodes
of HE were determined by history (patient and caregiver),
chart review, and if a patient was on treatment for HE. In
addition, history of other cirrhosis complications (ascites
and variceal hemorrhage) was recorded at enrollment. The
study protocol was approved by the McGuire VA and
Virginia Commonwealth University institutional review
boards.
PROMIS CAT Tool
The PROMIS CAT tools assess the following 11 domains:
(1) anger; (2) anxiety; (3) depression; (4) fatigue; (5) pain
behavior (behavior the patients perform as a result of the
pain); (6) pain interference (how does pain interfere with
their daily activities); (7) physical function;(8) satisfaction
with discretionary social activities (spending time in
recreation and friends, etc.); (9) satisfaction with social
roles (ability to perform roles expected toward family
members, work and potential dependents); (10) sleep dis-
turbance (how does impaired sleep impact their daily
activities); and (11) sleep-related impairment (how is the
1174 Dig Dis Sci (2017) 62:1173–1179
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sleep itself impaired). Each item of the PROMIS tools was
developed individually using patients’ representative
responses of the 2000 US Census [36]. There are: 29, 28,
95, 39, 41, 124, 27, 16, 12, and 14 questions in anger/
anxiety, depression, fatigue, pain behavior, pain interfer-
ence, physical function, sleep disturbance, sleep impair-
ment, social impairment and social roles domains,
respectively. The CAT presents a select group of questions
out of the aforementioned domains (between 4 and 12
questions per domain) for patients to answer. Based on the
responses to the first set of questions, the CAT continues to
present more questions until the responses satisfy the preset
reliability (80%). There are five possible responses for each
question (never, rarely, sometimes, often, and always) in
the domains with the exception of six possible responses in
the pain behavior domain (had no pain, never, rarely,
sometimes, often, and always). The results of the ques-
tionnaire are presented as a t score and a standard deviation
based on the standardized US population. The mean t score
is 50 and the standard deviation is 10. A typical printout of
the PROMIS CAT is found in the supplementary material.
Statistical Analysis
Most data were presented as mean ± standard deviation and
median interquartile range (IQR) in months where it was
appropriate. An unpaired t test was used for comparisons of
continuous variables and Chi-square or the Fisher exact tests
were used for categorical variables. A nominal p value of less
than or equal to 0.05 was considered significant. Significant
individual HRQOL domain and domain groups within
PROMIS tools were derived using principal component
analysis as described below. Cox proportional hazards
regression modeling was used for significant domain groups
for times to first hospitalization and re-hospitalization. Sta-
tistical analysis was performed with SPSS software for
Windows, version 23 (SPSS, Inc, Chicago, IL).
Significant Individual HRQOL Domains
To reduce the number of variables in the analysis and to
weigh individual PROMIS domains, an exploratory factor
analysis with a principal component extraction method and
varimax rotation was performed on the correlation matrix.
Initially, using a minimum eigenvalue criteria of 1, two
factors were identified that account for 68% of the vari-
ance. We wished to account for at least 70% of the vari-
ability, so we settled on a three-factor solution. The three-
factor exploratory analysis showed three major domain
groups which accounted for 77% of the variability. These
were daily function-related (fatigue, physical function,
social roles/activities, and sleep disturbance and impair-
ment), mood-related (anxiety, anger, and depression), and
pain-related (pain behavior/impact). Composite reliability
indices calculated for the variables identified as con-
tributing significantly to the HRQOL domains resulted in
values of 0.884 for the daily function domain group, 0.867
for the mood domain group and 0.868 for the pain domain
group.
Outcome Measures
Patients were followed prospectively at 3- to 6-month
intervals at our outpatient clinics. During follow-up, all
non-elective hospitalizations, death, and transplant were
recorded. Subsequent hospitalizations after liver trans-
plantation were not recorded. Non-elective hospitalizations
were further categorized as liver related or liver unrelated
(i.e., HE-related hospitalizations, renal ascites related,
infections, portal hypertension related bleeding). Elective
hospitalizations for procedures or studies were not
included.
If a patient could not be seen at our outpatient clinics,
they were tracked via our electronic medical system for any
hospitalizations, death, and transplant with confirmation
with telephone calls by the study staff. Time from initial
PROMIS evaluation to first hospitalization and subsequent
re-hospitalization(s) were recorded in months.
Outcome Prediction Models
Individual HRQOL domains were identified through factor
analysis for each patient using the PROMIS domains as
described above. Cox proportional hazards regression
modeling was then utilized if any of the identified indi-
vidual HRQOL domains had a significant impact of interest
(i.e., time to first hospitalization and time to re-hospital-
ization). Backward elimination was performed and only
individual HRQOL domains with a p value less than 0.05
were retained. In addition, a univariate analysis was per-
formed on known and potential variables for the outcomes
of interest. These were age, gender, education, MELD
score, serum sodium, albumin, ammonia, and complica-
tions of cirrhosis (history of HE, ascites, and variceal
bleeding). Variables that were significant on univariate
analysis were then combined with the three individual
domain groups and final models were constructed in a
similar manner as described above (i.e., backward elimi-
nation with a significance level of 0.05).
Results
A total of 286 patients met enrollment criteria. All patients
completed the PROMIS CAT at their first clinic visit.
Baseline demographic characteristics of the study
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population are shown in Table 1. The majority was male
(67%), with a mean age of 56.8 ± 7.8 years, and had
average years of education of 13.50 ± 2.37. The major
etiologies of cirrhosis were hepatitis C (38%) followed by
nonalcoholic steatohepatitis (24%) and alcoholic (10%).
Patients were followed for a mean of 38 months [me-
dian IQR of 22–47]. During the follow-up period, 89
patients (31%) were hospitalized [mean 12.5 months,
median IQR (3–27)]) and 34 patients (12%) were re-hos-
pitalized [mean 10.5 months, median IQR (3, 28)]. The
most common reason for the first hospitalization was liver
related (23%) of which overt HE (9%), renal ascites related
(6%), and infections (3%) were the most frequent etiolo-
gies. Similarly, the most common reason for re-hospital-
ization was liver-related (8%) of which overt HE (3%) and
infections (3%) were the most frequent etiologies. Fifty-
seven patients died (18%) and 73 patients were trans-
planted (26%) during the follow-up period.
PROMIS Analysis and Individual HRQOL Domains
All PROMIS individual domains were significantly
impaired compared to norms. The generation of domain
groups from PROMIS tools is shown in Table 2. Of the
domain groups identified, the daily function-related and
mood/pain-related were significantly impaired compared to
norms, p\ 0.001 and\ 0.01, respectively. Using multiple
comparison corrections, there was no significant difference
between PROMIS domains and use of narcotics, nons-
teroidal ant-inflammatory drugs, serotonin reuptake inhi-
bitors, serotonin–norepinephrine reuptake inhibitors, other
anti-depressants, and anti-anxiolytics.
Outcome Prediction
Time to first hospitalization was predicted by HE [hazards
ratio (HR) 1.5 (95% CI 1.01–2.50, p = 0.04)] and daily
function group [HR 1.4 (95% CI 1.1–1.8, p = 0.01)],
independently. In contrast the pain group was predictive for
time to re-hospitalization [(HR 1.6 (95% CI: 1.10–2.30,
p = 0.03)] as was HE [HR 2.1 (95% CI 1.10–4.30,
p = 0.03)] (Table 3).
Discussion
With the prolongation of survival in cirrhotic patients,
addressing individual domains that drive HRQOL is
important because it can quantify the impact of disease
[35], define response to treatment [12], and potentially
reduce costs by allocating resources to specific patient
populations [35]. In our study, we identified two major
domain groups within HRQOL, daily function and pain-
related PROMIS measures, that predicted hospitalizations
and re-hospitalizations independent of the MELD score
and other markers of disease severity.
Confirming prior studies using PROMIS [30] and other
tools [22–25], we found that majority of impairment was
Table 1 Patient demographics
N = 286
Age, mean ± SD 56.78 ± 7.77
Years of education, mean ± SD 13.50 ± 2.37
Etiology of cirrhosis, n (%)
HCV 108 (38%)
NASH 69 (24%)
Alcoholic 29 (10%)
Alcoholic and HCV 25 (9%)
Other 55 (19%)
Serum sodium (mmol/L) mean ± SD 138.00 ± 7.65
Serum albumin (g/dL) mean ± SD 3.44 ± 0.71
Serum ammonia (lmol/L) mean ± SD 52.67 ± 30.53
MELD score mean ± SD 12.70 ± 5.80
Ascites, n (%) 104 (36%)
History of HE, n (%) 113 (40%)
History of variceal bleeding, n (%) 38 (13%)
Narcotic use, n (%) 28 (10%)
NSAID use, n (%) 28 (10%)
Anti-anxiolytics use, n (%) 23 (8%)
SSRI/SSNRI use, n (%) 45 (16%)
Other anti-depressants use, n (%) 22 (8%)
PROMIS CAT tools, mean ± SD
Mood domain group
Anger 51.13 ± 8.27
Anxiety 53.87 ± 7.38
Depression 51.22 ± 8.64
Daily function domain group
Fatigue 55.38 ± 9.38
Physical function* 41.75 ± 8.03
Sleep disturbance 55.21 ± 10.33
Sleep-related impairment 55.01 ± 9.92
Discretionary social activities* 45.88 ± 7.98
Social roles* 43.21 ± 8.38
Pain domain group
Pain behavior 53.16 ± 9.63
Pain interference 55.02 ± 10.59
HE, hepatic encephalopathy; EVB, esophageal variceal bleed, M,
male; F, female; MELD, Model for End-Stage Liver Disease; NSAID,
nonsteroidal ant-inflammatory drug; SSRI, serotonin reuptake inhi-
bitor; SNRI, serotonin–norepinephrine reuptake inhibitors; PROMIS,
Patient-Reported Outcomes Measurement Information System; CAT,
computerized adaptive measurement system
* A low score indicates worse symptoms; a high score indicates
worse symptoms in the rest of the PROMIS scores
 Significantly different compared to PROMIS norms
1176 Dig Dis Sci (2017) 62:1173–1179
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related to the daily function groups. This is to be expected
given the impairments in physical function and sleep that
are prevalent in cirrhotic patients. Moreover, because of
their decrement in physical function, patients may feel
alienated in their community and family since they may
perceive themselves as non-productive members of society.
This can contribute to further impairment in social roles
and activities. Frailty, which studies the physical function
aspect of daily function-related domains, has already been
associated with survival and re-hospitalizations [12]. The
current study findings define the concomitant impact of
physical function with social role and sleep issues on
health-related outcomes. These findings point toward the
importance of assessing daily function concerns at each
clinical visit, both physical and mental, along with com-
municating the plan of care with patients and their family
members. Examples of this would be addressing nutritional
status to improve sarcopenia and muscle strength [36], and
sleep disturbances which can be a sign of impending HE
[37] or undiagnosed obstructive sleep apnea [38].
Translating subjective complaints into clinically rele-
vant objective outcomes is always challenging. This is
especially problematic in clinics where practitioners are
often not trained to handle PROs, which are usually beyond
their comfort zone. One example case would be in
addressing pain in cirrhosis where escalating analgesic
therapy is often complicated by concomitant clinical and
pharmacological interactions. A multidisciplinary approach
to pain is often lacking in most practices, which could
explain the significant impairment in the PROMIS pain
scores in our cohort. This is particularly important given
that up to 77% of cirrhotics experience moderate-to-severe
pain constantly [39], which is comparable to those with
lung cancer and colon cancer [40]. This can eventually lead
to mismanagement of pain medications or overtreatment,
increase in healthcare utilization [48], and in the current
study, re-hospitalizations. This was supported by a recent
study in which opioid use was associated with re-hospi-
talizations in cirrhotics recruited as inpatients [41]. Thus, it
is of high importance to incorporate evidence-based pain
Table 2 Domain groups within PROMIS measures—factor loadings
Domain groups PROMIS measures Factor 1 Factor 2 Factor 3 Final communality estimates
Daily function Social role 87 -11 -24 0.8329
Social activity 79 -13 -22 0.6837
Physical functioning 78 -3 -40 0.7647
Fatigue 266 38 31 0.6718
Sleep disturbance 266 41 12 0.6169
Sleep-related impairment 271 43 15 0.7140
Mood Anxiety -17 85 25 0.8065
Anger -14 83 4 0.7162
Depression -25 81 22 0.7590
Pain Pain behavior -30 27 88 0.9350
Pain impact -38 19 87 0.9392
The italic values indicate the domains that significantly impact that particular factor
* Overall, the variability in individual variables explained by the three factor solutions ranges from a low of approximately 62% for Sleep
Disturbance to a maximum of approximately 94% for pain impact and pain behavior
HRQOL, health-related quality of life; PROMIS, Patient-Reported Outcomes Measurement Information System
Table 3 Predictors of first hospitalization and re-hospitalization
Variables First hospitalization Re-hospitalization
Univariate Multivariate Univariate Multivariate
p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
History of HE 0.0007 2.07 (1.36,3.12) 0.04 1.57 (1.02,2.45) 0.007 2.58 (1.30,5.11) 0.03 2.14 (1.06,4.33)
Daily Function Group 0.0015 0.68 (0.53,0.86) 0.017 1.37 (1.06,1.77) 0.061 0.68 (0.46,1.02) – –
Mood Group 0.52 1.07 (0.87,1.33) – – 0.92 0.98 (0.70,1.39) – –
Pain Group 0.15 1.17 (0.94,1.46) – – 0.0185 1.62 (1.08,2.41) 0.02 1.56 (1.05,2.33)
MELD, Model for End-Stage Liver Disease; HE, hepatic encephalopathy; HR, hazard ratio; CI, confidence interval
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management strategies, such as the Centers of Disease
Control and Prevention guideline for prescribing opioids
for chronic pain [42], and encourage a multidisciplinary
approach with access to hospice and palliative care medi-
cine [43]. Lastly, while our study did not find any associ-
ation with mood and hospitalizations/re-hospitalizations,
these conditions are nevertheless important from a daily
function standpoint and in other studies to liver-related
mortality [44].
To our knowledge, this is the first study to identify
major individual domain groups within a HRQOL measure
and its impact on hospitalizations. However, there were
few limitations of the study. The first was a lack of a
separate validation cohort to substantiate our findings, and
thus further validation is required to build on the current
results. Second, we did not use death and or transplant as a
composite outcome since the focus of study was hospital-
izations. Lastly, we were unable to control for the number
of medications on discharge given its possible impact on
re-hospitalizations. Future work should study how treat-
ments affect these individual HRQOL domains and if
dedicated treatment reduces hospitalizations. Another
avenue for further research would be to evaluate the
effectiveness of these domains, along with our current
objective measures for determining liver transplant eligi-
bility and prognosis after transplant.
We conclude that daily function-related and pain-related
domain groups within PROMIS tools can predict hospi-
talizations and re-hospitalizations independent of objective
clinical measures in cirrhotic outpatients. Therefore, efforts
to incorporate PROs and their individual domains into
clinical practice could improve prognostication and help in
focused treatments.
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